SI-BONE Q2 revenue beats estimates, raises 2026 revenue outlook

SI-BONE

03/08/2026 21:23

Overview
US medical device maker's Q2 revenue rose 15% yr/yr, beating analyst expectations
Adjusted EBITDA for Q2 improved 178% to positive $2.8 mln
Company raised 2026 revenue guidance to 15-16% yr/yr growth

Outlook
SI-BONE raises 2026 revenue guidance to $231 mln-$233 mln, up from $230 mln-$233 mln
Company maintains 2026 gross margin guidance at about 79%
SI-BONE lowers 2026 operating expense growth guidance to about 12% from 12.5%

Result Drivers
U.S. PROCEDURE VOLUME - U.S. revenue growth benefited from a 14.9% increase in procedure volume
PHYSICIAN BASE EXPANSION - Active U.S. physician base grew 19% yr/yr
INTERNATIONAL PRODUCT UPTAKE - International revenue growth reflects strong initial reception for iFuse TORQ and iFuse TORQ TNT

Company press release: ID:nGNXf3T7z

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$56.01 mln
$55.34 mln (9 Analysts)
Q2 Net Loss
 
$4.09 mln
 
Q2 Gross Margin
 
79.50%
 
Q2 Loss Per Basic Share
 
$0.09
 
Q2 Operating Expenses
 
$49.35 mln
 
Q2 Operating income
 
-$4.81 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for SI-BONE Inc is $23.50, about 32.3% above its July 31 closing price of $17.76

Reuters Recommended Reads
Aug 3 - KKR to take medical-equipment maker Integer Holdings private in $5.7 billion deal
Aug 3 - Latigo, BlossomHill launch US IPOs as biotech listings rebound
Aug 3 - Supernus, Indivior merge to strengthen neuroscience drug portfolio

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)